-
China’s CDE Approves Multitude Therapeutics’ AMT-676 for Clinical Study in Solid Tumors
•
The Center for Drug Evaluation (CDE) of China has granted clinical study approval for Multitude Therapeutics Inc.’s proprietary injectable drug candidate, AMT-676, as indicated on the CDE website. The drug is intended for the treatment of solid tumors. AMT-676 is an antibody-drug conjugate (ADC) that targets CDH17, a gene situated…
-
Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment
•
SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics Inc. has entered into a licensing agreement with Denmark’s Adcendo ApS, a specialist in antibody drug conjugates (ADCs). The deal grants Adcendo exclusive global rights to develop and commercialize an anti-human tissue factor (TF) ADC,…
